FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 359:1143-1154 September 11, 2008 Number 11 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text PowerPoint Slide Set CME Exam Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

More than half a million patients receive the diagnosis of squamous-cell carcinoma of the head and neck worldwide each year. In this disease, which primarily affects the oropharynx, oral cavity, hypopharynx, and larynx, smoking and alcohol abuse are major risk factors. Symptoms vary, depending on the site of origin, and can include a sore throat, dysphagia, odynophagia, and hoarseness. On examination, patients often have an identifiable primary site and a palpable neck mass. A multidisciplinary approach is important in treating these patients, given the complexity of the treatment and the acute and long-term complications that result from chemotherapy, radiation therapy, . . . [Full Text of this Article]

Molecular Progression

Signal Transduction of EGFR

HPV and Antitumor Vaccine

Treatment

Strategies for Therapy

Concurrent Chemoradiotherapy

Definitive Chemoradiotherapy

Postoperative Chemoradiotherapy

Sequential Chemoradiotherapy

Docetaxel, Cisplatin, and Fluorouracil

            Induction Therapy

            Toxic Effects

Pros and Cons of Induction Therapy

Cetuximab

            Role of Biologic Agents

            With Radiation Therapy

            After Recurrence

Future Directions

Source Information

From the Department of Medical Oncology, Dana–Farber Cancer Institute; the Department of Medicine, Brigham and Women's Hospital; and the Department of Medicine, Harvard Medical School — all in Boston (R.I.H.); and the Department of Hematology–Oncology, Winship Cancer Institute, Emory University, Atlanta (D.M.S.).

Address reprint requests to Dr. Haddad at the Dana–Farber Cancer Institute, 44 Binney St., Boston, MA 02115, or at robert_haddad@dfci.harvard.edu.

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.